Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 109

1.

Dasatinib induces complete cytogenetic response and loss of F359C in an imatinib resistant chronic myelocytic leukemia patient.

Ustun C, Jillella AP, Salama ME.

Am J Hematol. 2009 Jun;84(6):386-7. doi: 10.1002/ajh.21409. No abstract available.

PMID:
19391130
[PubMed - indexed for MEDLINE]
2.

Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib.

Shah NP, Kim DW, Kantarjian H, Rousselot P, Llacer PE, Enrico A, Vela-Ojeda J, Silver RT, Khoury HJ, Müller MC, Lambert A, Matloub Y, Hochhaus A.

Haematologica. 2010 Feb;95(2):232-40. doi: 10.3324/haematol.2009.011452.

PMID:
20139391
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.

Hochhaus A, Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg SL, Corm S, Shah NP, Cervantes F, Silver RT, Niederwieser D, Stone RM, Dombret H, Larson RA, Roy L, Hughes T, Müller MC, Ezzeddine R, Countouriotis AM, Kantarjian HM.

Leukemia. 2008 Jun;22(6):1200-6. doi: 10.1038/leu.2008.84. Epub 2008 Apr 10.

PMID:
18401416
[PubMed - indexed for MEDLINE]
4.

Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia.

Tiribelli M, Latagliata R, Luciano L, Castagnetti F, Gozzini A, Cambrin GR, Annunziata M, Stagno F, Pregno P, Albano F, Abruzzese E, Musto P, Montefusco E, Fava C, Fanin R, Pane F, Rosti G, Breccia M, Alimena G, Vigneri P.

Ann Hematol. 2013 Jan;92(2):179-83. doi: 10.1007/s00277-012-1591-2. Epub 2012 Oct 10.

PMID:
23053188
[PubMed - indexed for MEDLINE]
5.

A novel insertion mutation of K294RGG within BCR-ABL kinase domain confers imatinib resistance: sequential analysis of the clonal evolution in a patient with chronic myeloid leukemia in blast crisis.

Sakai K, Ishikawa Y, Mori Y, Kobayashi M, Iriyama C, Ozawa Y, Suzuki T, Minami Y, Ishikawa K, Kaneda N, Naoe T, Kiyoi H.

Int J Hematol. 2011 Feb;93(2):237-42. doi: 10.1007/s12185-011-0766-2. Epub 2011 Jan 25.

PMID:
21264552
[PubMed - indexed for MEDLINE]
6.

BCR-ABL1 transcript at 3 months predicts long-term outcomes following second generation tyrosine kinase inhibitor therapy in the patients with chronic myeloid leukaemia in chronic phase who failed Imatinib.

Kim DD, Lee H, Kamel-Reid S, Lipton JH.

Br J Haematol. 2013 Mar;160(5):630-9. doi: 10.1111/bjh.12187. Epub 2012 Dec 24.

PMID:
23278256
[PubMed - indexed for MEDLINE]
7.

Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.

Abbott BL.

Clin Ther. 2012 Feb;34(2):272-81. doi: 10.1016/j.clinthera.2012.01.009. Epub 2012 Jan 27. Review.

PMID:
22285209
[PubMed - indexed for MEDLINE]
8.
9.

BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.

Wongboonma W, Thongnoppakhun W, Auewarakul CU.

Exp Mol Pathol. 2012 Apr;92(2):259-65. doi: 10.1016/j.yexmp.2012.01.007. Epub 2012 Jan 31.

PMID:
22314255
[PubMed - indexed for MEDLINE]
10.

Activity and safety of dasatinib as second-line treatment or in newly diagnosed chronic phase chronic myeloid leukemia patients.

Breccia M, Alimena G.

BioDrugs. 2011 Jun 1;25(3):147-57. doi: 10.2165/11591840-000000000-00000. Review.

PMID:
21528941
[PubMed - indexed for MEDLINE]
11.

Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value.

Hochhaus A, Müller MC, Radich J, Branford S, Kantarjian HM, Hanfstein B, Rousselot P, Kim DW, Lipton JH, Bleickardt E, Lambert A, Hughes TP.

Leukemia. 2009 Sep;23(9):1628-33. doi: 10.1038/leu.2009.156. Epub 2009 Jul 30.

PMID:
19641527
[PubMed - indexed for MEDLINE]
12.

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R).

Kantarjian H, Pasquini R, Lévy V, Jootar S, Holowiecki J, Hamerschlak N, Hughes T, Bleickardt E, Dejardin D, Cortes J, Shah NP.

Cancer. 2009 Sep 15;115(18):4136-47. doi: 10.1002/cncr.24504.

PMID:
19536906
[PubMed - indexed for MEDLINE]
Free Article
13.

Dasatinib in imatinib-resistant or -intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic.

Klamova H, Faber E, Zackova D, Markova M, Voglova J, Cmunt E, Novakova L, Machova-Polakova K, Moravcova J, Dvorakova D, Michalova K, Brezinova J, Oltova A, Jarosova M, Cetkovsky P, Indrak K, Mayer J.

Neoplasma. 2010;57(4):355-9.

PMID:
20429627
[PubMed - indexed for MEDLINE]
14.

F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib.

Oyekunle AA, Castagnetti F, Gugliotta G, Soverini S, Baccarani M, Rosti G.

Leuk Res. 2011 Jul;35(7):e118-20. doi: 10.1016/j.leukres.2011.03.021. Epub 2011 Apr 12. No abstract available.

PMID:
21489624
[PubMed - indexed for MEDLINE]
15.

Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase.

Kantarjian HM, Cortes J, La Rosée P, Hochhaus A.

Cancer. 2010 Mar 15;116(6):1419-30. doi: 10.1002/cncr.24928. Review.

PMID:
20120030
[PubMed - indexed for MEDLINE]
Free Article
16.

Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia.

Swords R, Alvarado Y, Cortes J, Giles FJ.

Curr Hematol Malig Rep. 2007 May;2(2):83-8. doi: 10.1007/s11899-007-0012-4. Review.

PMID:
20425355
[PubMed - indexed for MEDLINE]
17.

BCR-ABL mutational studies for predicting the response of patients with chronic myeloid leukaemia to second-generation tyrosine kinase inhibitors after imatinib failure.

Kwan TK, Ma ES, Chan YY, Wan TS, Liu HS, Sim JP, Yeung YM, Lie AK, Yip SF.

Hong Kong Med J. 2009 Oct;15(5):365-73.

PMID:
19801694
[PubMed - indexed for MEDLINE]
Free Article
18.

Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.

Wu J, Meng F, Kong LY, Peng Z, Ying Y, Bornmann WG, Darnay BG, Lamothe B, Sun H, Talpaz M, Donato NJ.

J Natl Cancer Inst. 2008 Jul 2;100(13):926-39. doi: 10.1093/jnci/djn188. Epub 2008 Jun 24.

PMID:
18577747
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia.

Milojkovic D, Nicholson E, Apperley JF, Holyoake TL, Shepherd P, Drummond MW, Szydlo R, Bua M, Foroni L, Reid A, Khorashad JS, de Lavallade H, Rezvani K, Paliompeis C, Goldman JM, Marin D.

Haematologica. 2010 Feb;95(2):224-31. doi: 10.3324/haematol.2009.012781. Epub 2009 Oct 14.

PMID:
19833633
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.

Guilhot F, Apperley J, Kim DW, Bullorsky EO, Baccarani M, Roboz GJ, Amadori S, de Souza CA, Lipton JH, Hochhaus A, Heim D, Larson RA, Branford S, Muller MC, Agarwal P, Gollerkeri A, Talpaz M.

Blood. 2007 May 15;109(10):4143-50. Epub 2007 Jan 30.

PMID:
17264298
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk